Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors
Christopher Heeschen, … , Stefanie Dimmeler, John P. Cooke
Christopher Heeschen, … , Stefanie Dimmeler, John P. Cooke
Published August 15, 2002
Citation Information: J Clin Invest. 2002;110(4):527-536. https://doi.org/10.1172/JCI14676.
View: Text | PDF
Article Vascular biology

A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors

  • Text
  • PDF
Abstract

Research Article

Authors

Christopher Heeschen, Michael Weis, Alexandra Aicher, Stefanie Dimmeler, John P. Cooke

×

Figure 5

Options: View larger image (or click on image) Download as PowerPoint
Murine model of hind limb ischemia: mecamylamine inhibits ischemia-induc...
Murine model of hind limb ischemia: mecamylamine inhibits ischemia-induced angiogenesis. Saline or increasing concentrations of mecamylamine were administered by daily intramuscular injections into the ischemic hind limb. (a) As compared with control, mecamylamine decreased capillary density. Results are shown as box plots displaying 25th and 75th percentiles as boxes and 5th and 95th percentiles as thin lines. n = 5; *P < 0.01 vs. control. i.m., intramuscular; s.c., subcutaneous. (b and c) At base line (no ischemia), the α7 subunit (red fluorescence) was not detectable by immunohistochemistry (capillaries identified by CD31, green fluorescence). (d and e) However, 7 days after induction of ischemia in the hind limb and no treatment, the α7 subunit of the nAChR was clearly detectable (red fluorescence) and mainly colocalized with CD31 (yellow fluorescence). Representative pictures are shown. (f) These results were confirmed by Western blot analyses demonstrating upregulation of the α7-nAChR subunit within 24 hours after onset of ischemia and a maximal effect at 7 days.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts